|1.||Chiron, Catherine: 6 articles (09/2012 - 04/2006)|
|2.||Brigo, Francesco: 4 articles (01/2015 - 01/2013)|
|3.||Czuczwar, Stanislaw J: 4 articles (08/2010 - 10/2006)|
|4.||Inoue, Yushi: 3 articles (07/2015 - 07/2012)|
|5.||Storti, Monica: 3 articles (01/2015 - 01/2013)|
|6.||Patsalos, Philip N: 3 articles (12/2013 - 11/2006)|
|7.||Fisher, Janet L: 3 articles (04/2011 - 01/2009)|
|8.||Dulac, Olivier: 3 articles (04/2011 - 06/2006)|
|9.||Luszczki, Jarogniew J: 3 articles (08/2010 - 10/2006)|
|10.||Rey, Elisabeth: 3 articles (02/2008 - 04/2006)|
04/01/2008 - "Considering its particular efficacy against severe myoclonic seizures in infancy (Dravet's syndrome), stiripentol has been awarded an orphan drug status for an adjunctive therapy of this difficult-to-treat condition."
01/01/2015 - "This study adopted a 'responder enriched' design and found no clear evidence of a reduction in seizure frequency (≥ 50% seizure reduction) (risk ratio (RR) 1.51, 95% confidence interval (CI) 0.81 to 2.82) nor evidence of seizure freedom (RR 1.18, 95% CI 0.31 to 4.43) when add-on stiripentol was compared with placebo. "
01/01/2014 - "The external validity of the study was limited because only responders to stiripentol (that is patients experiencing at least a 50% decrease in seizure frequency compared with baseline) were included in the randomised add on placebo-controlled double-blind phase. "
05/01/2014 - "Add-on stiripentol to CLB and VPA was well tolerated and significantly decreased clonic or tonic-clonic seizures in patients with Dravet syndrome."
01/01/2014 - " was no clear evidence of a reduction in seizure reduction 50% seizure reduction) (RR 1.51, 95% CI 0.81 to 2.82) or in seizure freedom (RR 1.18, 95% CI 0.31 to 4.43) with add on stiripentol compared with placebo. "
04/01/2011 - "This subunit selectivity may explain the greater clinical efficacy of stiripentol in childhood-onset epilepsies, including Dravet syndrome."
04/01/2008 - "In the form of an add-on therapy, stiripentol has proved to be effective in partial and atypical absence epilepsies. "
09/01/2012 - "The efficacy of stiripentol (STP) in Dravet Syndrome (DS) was discovered first in an exploratory study in pediatric pharmacoresistant epilepsies. "
01/01/2015 - "Randomised controlled add-on trials of stiripentol in patients with focal refractory epilepsy. "
01/01/2015 - "We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished and ongoing trials. "
|3.||Myoclonic Epilepsies (Myoclonic Encephalopathy)
08/01/2001 - "Stiripentol can be effective in severe myoclonic epilepsy in infancy. "
11/11/2000 - "Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. "
11/01/2012 - "Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome)."
01/01/2015 - "This is an updated version of the original Cochrane review published in Issue 11, 2013.Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for which stiripentol (STP) has been recently licensed as add-on therapy. "
01/01/2013 - "Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for whose treatment stiripentol (STP) has been recently licensed for add-on use. "
|4.||Partial Epilepsies (Epilepsy, Partial)
06/01/2006 - "Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design."
06/01/2006 - "The combination of stiripentol and carbamazepine proved to reduce seizure frequency in children with refractory partial epilepsy, although it failed to show a significant impact according to the escape criteria selected as the primary end point in the present study, for ethical reasons."
06/01/2006 - "Stiripentol, a new antiepileptic drug inhibiting cytochrome P450-enzymes, suggested some efficacy when combined with carbamazepine in an open trial in refractory partial epilepsy of childhood. "
|5.||Absence Epilepsy (Absence Seizure)
03/01/1993 - "Stiripentol in atypical absence seizures in children: an open trial."
11/01/1985 - "In these studies, stiripentol significantly reduced EEG interictal spike rates at mean plasma concentrations from 20 to 27 micrograms/ml in Study 2 and 11 to 14 micrograms/ml in Study 3. From these results, and those evinced in other studies, it appears that stiripentol should be evaluated for absence epilepsy and possible synergistic effects in polytherapy."
03/01/1993 - "Stiripentol (STP) was added to the antiepileptic drug (AED) regimen of 10 patients with uncontrolled atypical absence seizures (more than one seizure a day). "
08/01/1994 - "Stiripentol has been studied in patients with partial seizures, refractory epilepsy and refractory absence seizures with some efficacious results."
|1.||clobazam (HR 376)
|2.||Valproic Acid (Valproate, Semisodium)
|3.||Anticonvulsants (Antiepileptic Drugs)
|2.||Induced Hyperthermia (Thermotherapy)